Ceftobiprole for Treatment of MRSA Blood Stream Infection: A Case Series

References

• Falcó V, Burgos J, Almirante B. Ceftobiprole medocaril for the treatment of community-acquired pneumonia. Expert Opin Pharmacother. 2018;19(13):1503–1509. doi:10.1080/14656566.2018.151674930198789
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Flamm RK, Mendes RE, et al. Ceftobiprole activity against gram-positive and -negative pathogens collected from the United States in 2006 and 2016. Antimicrob Agents Chemother. 2018;63(1):e01566–18. doi:10.1128/AAC.01566-1830373807
   PubMed Web of Science ®Google Scholar
• Tascini C, Attanasio V, Ripa M, et al. Ceftobiprole for the treatment of infective endocarditis: a case series. J Glob Antimicrob Resist. 2019;20:56–59. doi:10.1016/j.jgar.2019.07.02031351247
   PubMed Web of Science ®Google Scholar
• Hamed K, Engelhardt M, Jones ME, et al. Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial. Future Microbiol. 2020;15(1):35–48. doi:10.2217/fmb-2019-033231918579
   PubMed Web of Science ®Google Scholar
• Lesens O, Methlin C, Hansmann Y, et al. Role of comorbidity in mortality related to staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity. Infect Control Hosp Epidemiol. 2003;24(12):890–896. doi:10.1086/50215614700403
   PubMed Web of Science ®Google Scholar
• Yousef SA, Mahmoud SY, Eihab MT. Prevalence of methicillin resistant Staphylococcus aureus in Saudi Arabia: systemic review and meta-analysis. Afr J Clin Exp Microbiol. 2013;14(3):146–154.
   Google Scholar
• Kourtis AP, Hatfield K, Baggs J, et al. Vital signs: epidemiology and recent trends in Methicillin-resistant and in Methicillin-susceptible staphylococcus aureus bloodstream infections - United States. MMWR Morb Mortal Wkly Rep. 2019;68(9):214–219. doi:10.15585/mmwr.mm6809e130845118
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–e55.21208910
   PubMed Web of Science ®Google Scholar
• Tong SYC, Lye DC, Yahav D, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA. 2020;323(6):527–537. doi:10.1001/jama.2020.010332044943
   PubMed Web of Science ®Google Scholar
• Davis JS, Van Hal S, Tong SYC. Combination antibiotic treatment of serious methicillin-resistant Staphylococcus aureus infections. Semin Respir Crit Care Med. 2015;36(1):3–16. doi:10.1055/s-0034-139690625643267
   PubMed Web of Science ®Google Scholar
• Dhand A, Sakoulas G. Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia. Clin Ther. 2014;36(10):1303–1316. doi:10.1016/j.clinthera.2014.09.005
   PubMed Web of Science ®Google Scholar
• Sieradzki K, Roberts RB, Haber SW, et al. The development of vancomycin resistance in a patient with methicillin-resistant staphylococcus aureus infection. N Engl J Med. 1999;340(7):517–523. doi:10.1056/NEJM19990218340070410021472
   PubMed Web of Science ®Google Scholar
• Geriak M, Haddad F, Rizvi K, et al. Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2019;63(5):e02483–18. doi:10.1128/AAC.02483-1830858203
   PubMed Web of Science ®Google Scholar
• Tattevin P, Basuino L, Bauer D, et al. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54(2):610–613. doi:10.1128/AAC.00886-0919917746
   PubMed Web of Science ®Google Scholar
• Mahajan SN, Shah JN, Hachem R, et al. Characteristics and outcomes of methicillin-resistant staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center. Oncologist. 2012;17(10):1329–1336. doi:10.1634/theoncologist.2012-002922707509
   PubMed Web of Science ®Google Scholar
• Baxi SM, Clemenzi-Allen A, Gahbauer A, et al. Vancomycin MIC does not predict 90-day mortality, readmission, or recurrence in a prospective cohort of adults with staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2016;60(9):5276–5284. doi:10.1128/AAC.00658-1627324762
   PubMed Web of Science ®Google Scholar
• Kalil AC, Van Schooneveld TC, Fey PD, et al. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. JAMA. 2014;312(15):1552–1564. doi:10.1001/jama.2014.636425321910
   PubMed Web of Science ®Google Scholar
• Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52(9):3315–3320. doi:10.1128/AAC.00113-0818591266
   PubMed Web of Science ®Google Scholar
• Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46(2):193–200. doi:10.1086/52466718171250
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54(6):755–771. doi:10.1093/cid/cir93522302374
   PubMed Web of Science ®Google Scholar
• Adani S, Bhowmick T, Weinstein MP, et al. Impact of vancomycin MIC on clinical outcomes of patients with methicillin-resistant staphylococcus aureus bacteremia treated with vancomycin at an institution with suppressed MIC reporting. Antimicrob Agents Chemother. 2018;62(4):e02512–17. doi:10.1128/AAC.02512-1729378704
   PubMed Web of Science ®Google Scholar